Unitedhealth Group

UNH Healthcare & Pharma 3/10 Low Risk

3/10

— 3 → 3 over 22 weeks

Sector avg: 3.1/10

Unitedhealth Group carries $77.7B in long-term debt, with $79.4B in scheduled principal maturities. DebtCanary scores UNH at 3/10, suggesting manageable refinancing risk.

Maturity Schedule

As of 2025-12-31 (latest SEC filing with maturity data). Debt actions taken after this date will only appear once SEC processes the relevant XBRL filing.

Period	Amount Due	% of Total
Year 1 (0-12 months)	$6.1B	7.7%
Year 2 (12-24 months)	$3.5B	4.4%
Year 3 (24-36 months)	$3.6B	4.5%
Year 4 (36-48 months)	$3.7B	4.6%
Year 5 (48-60 months)	$3.9B	4.9%
Beyond 5 Years	$58.7B	73.9%
Total Scheduled Maturities	$79.4B	100.0%

Key Metrics

Total Long-Term Debt

$77.7B

Near-Term (12mo)

$6.1B

Interest Coverage

4.7x

Debt/Equity

N/A

Cash Coverage

4.60x

Operating Income

$19.0B

Refinancing Cost Shock

If Unitedhealth Group refinanced the $9.6B due within 24 months at today's market yields, its annual interest bill would change by an estimated +$51M/year — about 0.3% of operating income.

Show the full calculation

Debt due within 24 months (Year 1 + Year 2 buckets): $9.6B

Current average rate = interest expense / interest-bearing debt = $4.0B / $84.2B = 4.76%

Synthetic rating bucket from coverage (operating income/interest 4.7x): A

Market yield for A bucket (ICE BofA via FRED, 2026-07-23): 5.29% (BAMLC0A3CAEY)

Rate change: 5.29% − 4.76% = +0.53 pp

Annual cost change: +0.53% × $9.6B = +$51M/yr

As share of operating income ($19.0B): 0.3%

Index-level estimate, not issuer-level bond pricing: the rating bucket is inferred from interest coverage (not an agency rating), and actual new-issue pricing depends on tenor, security, and market conditions. See the methodology.

Hidden future pain — added interest run-rate as the schedule rolls

+1yr

+$32M/yr (0.2%)

+2yr

+$51M/yr (0.3%)

+3yr

+$70M/yr (0.4%)

+4yr

+$89M/yr (0.5%)

+5yr

+$110M/yr (0.6%)

Cumulative run-rate change once all debt maturing by each horizon has refinanced. Assumes yields hold. Market-wide view on the Hidden Future Pain page.

What if yields move? market yield 5.29% (+0 bps)

24-month wall refinanced at that yield: = of operating income

Compare across all companies on the Refinancing Cliff Map →

How This Score Was Computed

Weighted average of 3 scored components (raw 3.13, rounded to 3). Weights of skipped components are redistributed proportionally among those scored.

Component	Value	Sub-Score	Weight Used
Near-Term Maturity Concentration Show calculation Year-1 maturities / Total scheduled maturities Year-1 maturities: $6.1B Total scheduled maturities: $79.4B	7.7%	3/10	40%
Interest Coverage Ratio Show calculation Operating income / Interest expense Operating income: $19.0B Interest expense: $4.0B	4.74x	5/10	33%
Debt-to-Equity Ratio Stockholders' equity was not reported.	N/A	—	not scored
Cash Coverage of Near-Term Debt Show calculation Cash & equivalents / Debt due within 12 months Cash & equivalents: $28.0B Near-term debt: $6.1B	4.60x	1/10	27%
Cash Runway Only scored when a company is burning cash. Operating cash flow is positive (or unreported), so runway isn't a constraint.	N/A	—	not scored

"Weight Used" shows each component's share after the weights of unscored components are redistributed. Full thresholds and formulas are on the methodology page.

Recent SEC Filings

Material disclosures from Unitedhealth Group's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date	Form	Details
2026-07-16	8-K	Earnings Results
2026-06-05	8-K	Shareholder Vote
2026-05-15	DEFA14A	Additional proxy materials
2026-05-11	8-K	Reg FD Disclosure
2026-05-05	10-Q	Quarterly report
2026-04-21	DEFA14A	Additional proxy materials
2026-04-21	DEF 14A	Proxy statement
2026-04-21	8-K	Earnings Results

Related Companies

Johnson & Johnson

JNJ

1/10

Debt: $41.4B 12mo: $2.0B

Pfizer

PFE

5/10

Debt: N/A 12mo: $3.9B

AbbVie

ABBV

4/10

Debt: $64.5B 12mo: $6.0B

Merck &

MRK

4/10

Debt: $49.1B 12mo: $2.6B

Eli Lilly

LLY

4/10

Debt: $29.5B 12mo: N/A

Bristol Myers Squibb

BMY

5/10

Debt: $44.1B 12mo: $2.0B

Amgen

AMGN

5/10

Debt: $57.3B 12mo: $4.6B

Gilead Sciences

GILD

2/10

Debt: $22.2B 12mo: $1.3B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-31. Filing date: 2026-05-05. Data last fetched: 2026-07-26. Maturity schedules reflect the company's most recently reported debt repayment obligations. This company does not tag the standard LongTermDebt concept; its debt figure comes from DebtLongtermAndShorttermCombinedAmount. Data quality: Partial.
View SEC EDGAR filings for Unitedhealth Group →